These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 386307)

  • 1. An evaluation of bromocriptine in the treatment of Parkinson's disease.
    Mackenzie RA; Lance JW
    Clin Exp Neurol; 1978; 15():228-36. PubMed ID: 386307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A double-blind trial of bromocriptine in Parkinson's disease.
    Mackenzie RA; Lance JW
    Med J Aust; 1978 Nov; 2(3 Suppl):27-8. PubMed ID: 370527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH; Ha JH; Cho IS; Lee MC
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bromocriptine: problems with low-dose de novo therapy in Parkinson's disease.
    Grimes JD; Delgado MR
    Clin Neuropharmacol; 1985; 8(1):73-7. PubMed ID: 3978651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bromocriptine versus placebo in levodopa treated patients with Parkinson's disease.
    Gron U
    Acta Neurol Scand; 1977 Sep; 56(3):269-73. PubMed ID: 333855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Sydney multicentre study of Parkinson's disease. The first 18 months.
    Hely MA; Morris JG; Rail D; O'Sullivan DJ; Williamson PM; Genge S; Reid WG; Broe GA
    Med J Aust; 1987 Feb; 146(4):195-8. PubMed ID: 3553878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose bromocriptine in the early phases of Parkinson's disease.
    Tolosa E; Blesa R; Bayes A; Forcadell F
    Clin Neuropharmacol; 1987 Apr; 10(2):168-74. PubMed ID: 3332610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Levodopa + carbidopa + entacapone. Entacapone: a second look: new preparations. Parkinson's disease: a modest effect.
    Prescrire Int; 2005 Apr; 14(76):51-4. PubMed ID: 15875340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of bromocriptine and levodopa as first line treatment of Parkinson's disease: results of a 3-year prospective randomized study].
    Montastruc JL; Rascol O; Rascol A
    Rev Neurol (Paris); 1990; 146(2):144-7. PubMed ID: 2181588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.
    Rascol O; Fabre N; Blin O; Poulik J; Sabatini U; Senard JM; Ané M; Montastruc JL; Rascol A
    Mov Disord; 1994 Jul; 9(4):437-40. PubMed ID: 7969211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease.
    Schrag AE; Brooks DJ; Brunt E; Fuell D; Korczyn A; Poewe W; Quinn NP; Rascol O; Stocchi F
    Clin Neuropharmacol; 1998; 21(3):169-75. PubMed ID: 9617508
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sustained bromocriptine therapy in 50 previously untreated patients with Parkinson's disease.
    Stern GM; Lees AJ
    Adv Neurol; 1983; 37():17-21. PubMed ID: 6858771
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The addition of bromocriptine to long-term dopa therapy in Parkinson's disease.
    Selby G
    Clin Exp Neurol; 1989; 26():129-39. PubMed ID: 2701877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A nation-wide collaborative study on the long-term effects of bromocriptine in patients with Parkinson's disease. First interim report in Japan.
    Nakanishi T; Mizuno Y; Goto I; Iwata M; Kanazawa I; Kowa H; Mannen T; Nishitani H; Ogawa N; Takahashi A
    Eur Neurol; 1988; 28 Suppl 1():3-8. PubMed ID: 3378560
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of bromocriptine (Parlodel) and levodopa-carbidopa (Sinemet) for treatment of "de novo" Parkinson's disease patients.
    Libman I; Gawel MJ; Riopelle RJ; Bouchard S
    Can J Neurol Sci; 1987 Nov; 14(4):576-80. PubMed ID: 3319120
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Bromocriptine as the 1st treatment of Parkinson's disease. Long term results].
    Rascol A; Montastruc JL; Guiraud-Chaumeil B; Clanet M
    Rev Neurol (Paris); 1982; 138(5):401-8. PubMed ID: 7146724
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early combination therapy with bromocriptine and levodopa in Parkinson's disease.
    Factor SA; Weiner WJ
    Mov Disord; 1993 Jul; 8(3):257-62. PubMed ID: 8341289
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of deprenyl and levodopa on the progression of Parkinson's disease.
    Olanow CW; Hauser RA; Gauger L; Malapira T; Koller W; Hubble J; Bushenbark K; Lilienfeld D; Esterlitz J
    Ann Neurol; 1995 Nov; 38(5):771-7. PubMed ID: 7486869
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of administration of low doses of bromocriptine and levodopa in the early treatment of Parkinson disease].
    Sternić N; Kostić V
    Srp Arh Celok Lek; 1992; 120(1-2):1-5. PubMed ID: 1641693
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.